Biomarkers of bone remodeling in ankylosing spondylitis patients using nonsteroidal anti-inflammatory drugs: results of an ETHICS research program


Cite item

Full Text

Abstract

Aim. To evaluate changes in the concentration of biomarkers for osteoproliferation and bone resorption in ankylosing spondylitis (AS) patients treated with nonsteroidal anti-inflammatory drugs (NSAIDs) in different regimens. Subjects and methods. Forty patients with AS (according to the modified New York criteria), who had BASDAI ≥ 4.0 at baseline and at 52 weeks of on-demand NSAID treatment were examined and randomized into 2 groups: 1) 30 patients who used continuously oral tenoxicam 20 mg daily (a study group); 2) 10 patients who continued previous therapy (a comparison group). BASDAI and ASDAS were calculated; the serum levels of C-reactive protein, C-terminal type I procollagen propeptide (PICP), and C-terminal telopeptide of type I collagen (CTX-I) were measured at baseline and at 52 and 56 weeks of treatment. A control group consisted of 19 healthy volunteers. Results. The continuous use of NSAIDs (tenoxicam) decreased higher baseline BASDAI and ASDAS scores. There were no changes in the indicators of AS activity in the patients who took on-demand NSAIDs. Baseline CTX-I levels did not differ between the patients with AS and the healthy individuals; those declined during continuous intake of tenoxicam and remained unchanged during on-demand administration. In the patients with AS, baseline PICP levels exceeded those in the healthy individuals. In the tenoxicam-treated patients, the concentrations of PICP at baseline and at 52 and 56 weeks were 17.1±9.0, 16.8±9.9, and 13.29±6.7 ng/ml, respectively (p=0.0001 for differences between the baseline and week 56 levels); in the comparison group, PICP levels did not change statistically significantly (p≥0.05 for all intergroup comparisons). Conclusion. Changing the inefficient long-term on-demand use of NSAIDs to their continuous intake is associated with a rapid decrease in clinical AS activity (within 4 weeks) with a reduction in the higher baseline concentration of the marker for osteoproliferation and in the normal level of the marker for bone resorption.

About the authors

I Z Gaydukova

ФГБОУ ВО «Северо-Западный государственный медицинский университет им. И. И. Мечникова» Минздрава России

Санкт-Петербург, Россия

A V Aparkina

ФГБОУ ВО «Северо-Западный государственный медицинский университет им. И. И. Мечникова» Минздрава России

Санкт-Петербург, Россия

E V Khondkaryan

ФГБОУ ВО «Северо-Западный государственный медицинский университет им. И. И. Мечникова» Минздрава России

Санкт-Петербург, Россия

A P Rebrov

ФГБОУ ВО «Северо-Западный государственный медицинский университет им. И. И. Мечникова» Минздрава России

Санкт-Петербург, Россия

References

  1. Эрдес Ш.Ф., Бадокин В.В., Бочкова А.Г., Бугрова О.В., Гайдукова И.З., Годзенко А.А., Дубиков А.А., Дубинина Т.В., Иванова О.Н., Коротаева Т.В., Лапшина С.А., Несмеянова О.Б., Никишина И.П., Оттева Э.Н., Раскина Т.А., Ребров А.П., Румянцева О.А., Ситало А.В., Смирнов А.В. О терминологии спондилоартритов. Научно-практическая ревматология. 2015;53(6):657-660. https://doi.org/10.14412/1995-4484-2015-657-660
  2. van der Heijde D, Ramiro S, Landewé R, Baraliakos X, Van den Bosch F, Sepriano A, Regel A, Ciurea A, Dagfinrud H, Dougados M, van Gaalen F, Géher P, van der Horst-Bruinsma I, Inman RD, Jongkees M, Kiltz U, Kvien TK, Machado PM, Marzo-Ortega H, Molto A, Navarro-Compàn V, Ozgocmen S, Pimentel-Santos FM, Reveille J, Rudwaleit M, Sieper J, Sampaio-Barros P, Wiek D, Braun J. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017. https://doi.org/10.1136/annrheumdis-2016-210770.
  3. Schoels MM, Braun J, Dougados M, Emery P, Fitzgerald O, Kavanaugh A, Kvien TK, Landewé R, Luger T, Mease P, Olivieri I, Reveille J, Ritchlin C, Rudwaleit M, Sieper J, Smolen JS, Wit Md, van der Heijde D. Treating axial and peripheral spondyloarthritis, including psoriatic arthritis, to target: results of a systematic literature search to support an international treat-to-target recommendation in spondyloarthritis. Ann Rheum Dis. 2014;73(1):238-242. https://doi.org/10.1136/annrheumdis-2013-203860
  4. Wendling D. Treating to target in axial spondyloarthritis: defining the target and the arrow. Expert Rev Clin Immunol. 2015;11(6):691-693. https://doi.org/10.1586/1744666X.2015.1039514
  5. Baraliakos X, Listing J, Brandt J, Haibel H, Rudwaleit M, Sieper J, Braun J. Radiographic progression in patients with ankylosing spondylitis after 4 yrs of treatment with the anti-TNF-alpha antibody infliximab. Rheumatology (Oxford). 2007;46(9):1450-1453.
  6. Reveille JD. Biomarkers for diagnosis, monitoring of progression, and treatment responses in ankylosing spondylitis and axial spondyloarthritis. Clin Rheumatol. 2015;34(6):1009-18. https://doi.org/10.1007/s10067-015-2949-3
  7. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984;27(4):361-368.
  8. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994;21(12):2286-2291.
  9. Brandt J, Listing J, Sieper J, Rudwaleit M, van der Heijde D, Braun J.Development and preselection of criteria for short term improvement after anti-TNF alpha treatment in ankylosing spondylitis. Ann Rheum Dis. 2004;63(11):1438-1444. https://doi.org/10.1136/ard.2003.016717
  10. van der Heijde D1, Lie E, Kvien TK, Sieper J, Van den Bosch F, Listing J, Braun J, Landewé RASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosingspondylitis. Ann Rheum Dis. 2009;68(12):1811-1818. https://doi.org/10.1136/ard.2008.100826
  11. Machado P1, Landewé R, Lie E, Kvien TK, Braun J, Baker D, van der Heijde D; Assessment of SpondyloArthritis international SocietyAnkylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activitystates and improvement scores. Ann Rheum Dis. 2011;70(1):47-53. https://doi.org/10.1136/ard.2010.138594
  12. Calin A, Garrett S, Whitelock H, Kennedy LG, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol. 1994;21(12):2281-2285.
  13. Heuft-Dorenbosch L, Spoorenberg A, van Tubergen A, et al. Assessment of enthesitis in ankylosing spondylitis. Ann Rheum Dis. 2003;62(2):127-132.
  14. Реброва О.Ю., ред. В кн.: Реброва О.Ю. Статистический анализ медицинских данных. Применение пакета прикладных программ STATISTICA. М.: Медиа-Сфера. 2002.
  15. Der-Yuan Chen, Yi-Ming Chen,Hsin-Hua Chen, Chia-Wei Hsieh, Chi-Chen Lin and Joung-Liang Lan. Increasing levels of circulating Th17 cells and interleukin-17 in rheumatoid arthritis patients with an inadequate response to anti-TNF-α therapy. Arthritis Res Ther. 2011;13(4):R126 Published online 2011. https://doi.org/10.1186/ar3431
  16. Fernanda Manente Milanez, Carla G. S. Saad, Vilma T. Viana, Júlio C. B. Moraes, Grégory Vinícius Périco, Percival Degrava Sampaio-Barros, Célio R. Goncalves, and Eloísa Bonfá. IL-23/Th17 axis is not influenced by TNF-blocking agents in ankylosing spondylitis patients. Arthritis Res Ther. 2016;18:52. https://doi.org/10.1186/s13075-016-0949-6
  17. C. Henrique Alves, Eric Farrell, Marijn Vis, Edgar M. Colin, and Erik Lubberts. Animal Models of Bone Loss in Inflammatory Arthritis: from Cytokines in the Bench to Novel Treatments for Bone Loss in the Bedside — a Comprehensive Review Clin Rev Allergy Immunol. 2016;51:27-47. https://doi.org/10.1007/s12016-015-8522-7
  18. Braun J, Baraliakos X, Deodhar A, Baeten D, Sieper J, Emery P, Readie A, Martin R, Mpofu S, Richards HB; MEASURE 1 study group. Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study. Ann Rheum Dis. 2016 Dec 13. pii: annrheumdis-2016-209730. https://doi.org/10.1136/annrheumdis-2016-209730.
  19. Verstappen SM, Poole AR, Ionescu M, King LE, Abrahamowicz M, Hofman DM, Bijlsma JW, Lafeber FP; Utrecht Rheumatoid Arthritis Cohort Study group (SRU). Radiographic joint damage in rheumatoid arthritis is associated with differences in cartilage turnover and can be predicted by serum biomarkers: an evaluation from 1 to 4 years after diagnosis. Arthritis Res Ther. 2006;8(1):R31. https://doi.org/10.1186/ar1882
  20. Dénarié D, Constant E, Thomas T, Marotte H. Could biomarkers of bone, cartilage or synovium turnover be used for relapse prediction in rheumatoid arthritis patients? Mediators Inflamm. 2014;2014:537324. https://doi.org/10.1155/2014/537324

Copyright (c) 2017 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies